A COMBINATION STUDY OF DURVALUMBAB PLUS OLAPARIB IN AN UNSELECTED POPULATION WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)

The Geneva Foundation

Investigators